ArticleJAC-antimicrobial resistance2021
Characterization of
Article in JAC-antimicrobial resistance, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 13 citations in OpenAlex.
- Dissemination of antimicrobial resistance in surface waters: surveillance of enterococci and coliform bacteria in Slovakia.International microbiology : the official journal of the Spanish Society for Microbiology · 2026Article
- Real-world outcomes and safety of colistin therapy in children with multidrug-resistant gram-negative infections: a nine-year experience.European journal of pediatrics · 2026Article
- Correlation between the mutation rates for ampC derepression and species or ampC genotypes in Enterobacter cloacae complex.BMC microbiology · 2025Article
- Characterization ofAntibiotics (Basel, Switzerland) · 2025Article
- Molecular epidemiology and β-lactam resistance mechanisms ofMicrobiology spectrum · 2025Article
- Genomic characterization of a multidrug-resistantFrontiers in microbiology · 2025Article
- Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant gram-negative bacteria.Communications medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo evaluate the antimicrobial susceptibility and resistance mechanisms to β-lactams among
methods2571
resultsOverall susceptibility to ceftazidime and cefepime were 73.9% and 91.2% among
conclusionsHyperproduction of chromosomal AmpC appears to be the most common mechanism of resistance to ceftazidime and/or cefepime in
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.